Home / Europe / Belgium / Life Sciences & Healthcare

Life Sciences & Healthcare

With over 480 international specialist lawyers across CMS and the support of the Lifesciences Asia-Pacific Network (LAN), we understand the scientific and commercial as well as the legal imperatives affecting your lifesciences and healthcare business. We work with and have established long-term relationships with the top 100 lifesciences and healthcare companies in the areas of pharmaceuticals, medical devices, biotechnology, agriculture and food.

Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology, medical devices and diagnostics. As members and partners of major industry associations such as the ABPI, ABHI, BIVDA, PAGB, EFPIA and EUCOMED we help shape the legal frameworks impacting the lifesciences and healthcare sectors. 

We regularly advise our clients on their day-to-day operational needs such as, patent enforcement, commercial and clinical trial agreements, protection of privacy and trade secrets, e-health, support with advertisement and promotion of medicine, public sector procurement, pricing and reimbursement as well as regulatory advice. 

Equally, when you need specialist advice in the area of lifesciences and healthcare for strategic agreements, planning a corporate transaction or embarking on litigation (whether product liability or otherwise), we have a team that is well versed in the industry issues to help you.

"Very hands-on knowledge and ability to provide very practical examples to the business. Feedback received was really what we needed, being very hands on, easy to understand feedback to specific practical questions."

Feedback from a client about the department - Legal 500, 2022

"CMS' cross-practice collaboration and multilingual capabilities make it a popular choice for a varied roster of pharmaceutical heavyweights, industry associations and hospital groups. The team is especially renowned for its public procurement capabilities, working with some of the largest Europe-wide governing bodies on high-profile, cross-border projects. Joint practice heads Bruno Fonteyn and Virginie Dor are noted for their expertise in health sector regulation and EU-wide health and social care procurement mandates, respectively."

Legal 500, 2022

Feed

07/06/2022
Trade secret laws and reg­u­la­tions in Bel­gi­um
Gen­er­al 1. Has the Dir­ect­ive (EU) 2016/943 of the European Par­lia­ment and of the Coun­cil of 8 June 2016 on the pro­tec­tion of un­dis­closed know-how and busi­ness in­form­a­tion (trade secrets) against their...
Comparable
01/06/2022
CMS Next
What’s next? In a world of ever-ac­cel­er­at­ing change, stay­ing ahead of the curve and know­ing what’s next for your busi­ness or sec­tor is es­sen­tial.At CMS, we see ourselves not only as your leg­al ad­visers but also as your busi­ness part­ners. We work to­geth­er with you to not only re­solve cur­rent is­sues but to an­ti­cip­ate fu­ture chal­lenges and in­nov­ate to meet them.With our latest pub­lic­a­tion, CMS Next, our ex­perts will reg­u­larly of­fer you in­sights in­to and fresh per­spect­ives on a range of is­sues that busi­nesses have to deal with – from ESG agen­das to re­struc­tur­ing after the pan­dem­ic or fa­cing the di­git­al trans­form­a­tion. We will also share with you more about the work that we are do­ing for our cli­ents, help­ing them in­nov­ate, grow and mit­ig­ate risk.To be able to provide you with the best sup­port, we im­merse ourselves in your world to un­der­stand your leg­al needs and chal­lenges. However, it is equally im­port­ant that you know who we are and how we can work with you. So, we in­vite you to meet our ex­perts and catch a glimpse of what is hap­pen­ing in­side CMS.En­joy read­ing this pub­lic­a­tion, which we will up­date reg­u­larly with new con­tent.CMS Ex­ec­ut­ive Team
26/05/2022
Schrems II: Re­ac­tions to the judge­ment and the su­per­vis­ory au­thor­it­ies'...
“Schrems II”: Opin­ions of the su­per­vis­ory au­thor­it­ies on Schrems II and re­com­mend­a­tions on the im­ple­ment­a­tion of the judge­ment in in­ter­na­tion­al data trans­fers On 16 Ju­ly 2020, the Court of Justice...
19/05/2022
Can­nabis law and le­gis­la­tion in Bel­gi­um
Med­ic­al use In prin­ciple, the cul­tiv­a­tion, im­port, sale and pos­ses­sion of (medi­cin­al or re­cre­ation­al) can­nabis is not al­lowed un­der Bel­gian law.An ex­cep­tion is made for the cul­tiv­a­tion of hemp with a...
04/2022
CMS Life Sci­ences & Health­care Glob­al Bro­chure
With big deals fuel­ling re­cord levels of M&A activ­ity, a steady stream of in­nov­at­ive and dis­rupt­ive tech­no­lo­gies, new and in­creas­ingly com­plex reg­u­lat­ory chal­lenges and a thriv­ing start-up com­munity...
08/04/2022
The Pro­posed Dir­ect­ive on Cor­por­ate Sus­tain­ab­il­ity Due Di­li­gence – a step...
The Pro­posed Dir­ect­ive on Cor­por­ate Sus­tain­ab­il­ity Due Di­li­gence (the “CSDD Pro­pos­al”), pub­lished on 23 Feb­ru­ary 2022, aims to im­pose ob­lig­a­tions on com­pan­ies, their sub­si­di­ar­ies and their value chains...
05/04/2022
Re­cent up­dates to the EPO Guidelines for Ex­am­in­a­tion rel­ev­ant to in­ven­tions...
An amended ver­sion of the EPO Guidelines for Ex­am­in­a­tion entered in­to force on 1 March 2022, su­per­sed­ing the edi­tion of March 2021. Here we re­view the up­dates rel­ev­ant to in­ven­tions in the field of bi­o­tech­no­logy...
17/02/2022
Sig­ni­fic­ant Con­sulta­tion on pro­posed re­vi­sions to REACH
Un­til 15 April 2022, the European Com­mis­sion (“EC”) is con­sult­ing on pro­posed re­vi­sions of REACH, (Reg­u­la­tion (EC) No 1907/2006 as amended), the corner­stone of EU chem­ic­als reg­u­la­tion. REACH aims...
01/02/2022
UPC: Is it fi­nally here?
New tem­por­ary pro­vi­sions at the European Pat­ent Of­fice re­lat­ing to the Unit­ary Pat­ent The European Pat­ent Of­fice (EPO) is­sued 3 new no­tices on 19 Janu­ary 2022 about the Unit­ary Pat­ent. They are:...
01/12/2021
A piece of pat­ent his­tory has been made con­cern­ing pat­entab­il­ity of com­puter...
In March 2021 the En­larged Board of Ap­peal of the European Pat­ent Of­fice answered ques­tions con­cern­ing pat­entab­il­ity of com­puter soft­ware sim­u­la­tions in case G1/19.  A Tech­nic­al Board of Ap­peal has now...
15/11/2021
CMS Bel­gi­um and CMS France ad­vised Gryphon In­vestors on their ac­quis­i­tion...
CMS Bel­gi­um and CMS France suc­cess­fully ad­vised, along­side Kirk­land & El­lis, Gryphon In­vestors (“Gryphon”), a lead­ing middle-mar­ket private equity firm, on the Bel­gian and French as­pects of Gryphon’s...
10/11/2021
COV­ID and ViCo: The End?
En­larged Board of Ap­peal de­cision G1/21 Back­ground Fol­low­ing an EPO press re­lease on 16 Ju­ly 2021, the En­larged Board of Ap­peal’s (EBA) de­cision on video­con­fer­en­cing (ViCo) was re­leased last week. We...